Possibilities and limitations of the use of beta-blockers in patients with cardiovascular disease and chronic obstructive pulmonary disease

In medical literature, increasing attention is paid to comorbidities in patients with chronic obstructive pulmonary disease (COPD). In clinical practice, physicians often hesitate to prescribe beta-blockers (β1-adrenoblockers) to COPD patients. This article summarized new results of using beta-blockers in patients with COPD. According to reports, the selective β1-blocker treatment considerably increases the survival rate of patients with COPD and ischemic heart disease, particularly after myocardial infarction (MI), and with chronic heart failure (CHF). The benefit of administering selective β1-blockers to patients with CHF and/or a history of MI overweighs a potential risk related with the treatment even in patients with severe COPD. Convincing data in favor of the β1-blocker treatment in COPD patients without the above-mentioned comorbidities are not available. At present, the selective β1-blocker treatment is considered safe for patients with cardiovascular diseases and COPD. For this reason, selective β1-blockers, such as bisoprolol, metoprolol or nebivolol can be used in managing this patient cohort. Nonselective β1-blockers may induce bronchospasm and are not recommended for COPD patients. For the treatment with β-blockers with intrinsic sympathomimetic activity, the probability of bronchial obstruction in COPD patients is lower; however, drugs of this pharmaceutical group have not been compared with cardioselective beta-blockers. For safety reasons, the beta-blocker treatment should be started outside exacerbation of COPD and from a small dose. Careful monitoring is recommended for possible new symptoms, such as emergence/increase of shortness of breath, cough or changes in dosing of other drugs (for example, increased frequency of using short-acting bronchodilators).

1. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. European Respiratory Journal. 2019;53(5):1900164. DOI: 10.1183/13993003.00164-2019

2. Corrao S, Brunori G, Lupo U, Perticone F. Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities. European Respiratory Review. 2017;26(145):160123. DOI: 10.1183/16000617.0123-2016

3. Karoli N.A., Orlova E.E., Markova A.V., Rebrov A.P. Comorbidity in chronic obstructive lung disease. Russian Heart Failure Journal. 2008;9(1):41–3.

4. Miller J, Edwards LD, Agustí A, Bakke P, Calverley PMA, Celli B et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respiratory Medicine. 2013;107(9):1376–84. DOI: 10.1016/j.rmed.2013.05.001

5. Lipworth B, Wedzicha J, Devereux G, Vestbo J, Dransfield MT. Beta-blockers in COPD: time for reappraisal. The European Respiratory Journal. 2016;48(3):880–8. DOI: 10.1183/13993003.01847-2015

6. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and Therapeutic Challenges in Patients With Coexistent Chronic Obstructive Pulmonary Disease and Chronic Heart Failure. Journal of the American College of Cardiology. 2007;49(2):171–80. DOI: 10.1016/j.jacc.2006.08.046

7. Mareev V.Yu., Fomin I.V., Ageev F.T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8–158. DOI: 10.18087/cardio.2475

8. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2005;4:CD003566. DOI: 10.1002/14651858.CD003566.pub2

9. Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM: An International Journal of Medicine. 2005;98(7):493–7. DOI: 10.1093/qjmed/hci080

10. Lipworth B, Skinner D, Devereux G, Thomas V, Ling Zhi Jie J, Martin J et al. Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease. Heart. 2016;102(23):1909–14. DOI: 10.1136/heartjnl-2016-309458

11. Albouaini K, Andron M, Alahmar A, Egred M. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. International Journal of Chronic Obstructive Pulmonary Disease. 2007;2(4):535–40. PMID: 18268926

12. Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal of Heart Failure. 2009;11(3):292–8. DOI: 10.1093/eurjhf/hfp001

13. Neef PA, McDonald CF, Burrell LM, Irving LB, Johnson DF, Steinfort DP. Beta-blockers are under-prescribed in patients with chronic obstructive pulmonary disease and co-morbid cardiac disease: Brief Communications. Internal Medicine Journal. 2016;46(11):1336–40. DOI: 10.1111/imj.13240

14. Lim KP, Loughrey S, Musk M, Lavender M, Wrobel J. Beta-blocker under-use in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease. 2017;12:3041–6. DOI: 10.2147/COPD.S144333

15. Rasmussen DB, Bodtger U, Lamberts M, Nicolaisen SK, Sessa M, Capuano A et al. Beta-blocker, aspirin, and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. European Heart Journal - Quality of Care and Clinical Outcomes. 2020;6(1):23–31. DOI: 10.1093/ehjqcco/qcy063

16. Parkin L, Quon J, Sharples K, Barson D, Dummer J. Underuse of beta‐blockers by patients with COPD and co‐morbid acute coronary syndrome: A nationwide follow‐up study in New Zealand. Respirology. 2020;25(2):173–82. DOI: 10.1111/resp.13662

17. Ling Y, Saleem W, Shee CD. Concomitant use of -blockers and 2-agonists. European Respiratory Journal. 2008;31(4):905–6. DOI: 10.1183/09031936.00153707

18. Short PM, Lipworth SIW, Elder DHJ, Schembri S, Lipworth BJ. Effect of blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011;342:d2549. DOI: 10.1136/bmj.d2549

19. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF et al. Differences Between Beta-Blockers in Patients With Chronic Heart Failure and Chronic Obstructive Pulmonary Disease: a randomized crossover trial. Journal of the American College of Cardiology. 2010;55(17):1780–7. DOI: 10.1016/j.jacc.2010.01.024

20. Bhatt SP, Wells JM, Kinney GL, Washko GR, Budoff M, Kim Y et al. β-Blockers are associated with a reduction in COPD exacerbations. Thorax. 2016;71(1):8–14. DOI: 10.1136/thoraxjnl-2015-207251

21. Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-Blockers Reduced the Risk of Mortality and Exacerbation in Patients with COPD: A Meta-Analysis of Observational Studies. PLoS ONE. 2014;9(11):e113048. DOI: 10.1371/journal.pone.0113048

22. Rutten FH. β-Blockers May Reduce Mortality and Risk of Exacerbations in Patients With Chronic Obstructive Pulmonary Disease. Archives of Internal Medicine. 2010;170(10):880–7. DOI: 10.1001/archinternmed.2010.112

23. Nielsen AO, Pedersen L, Sode BF, Dahl M. β-Blocker Therapy and Risk of Chronic Obstructive Pulmonary Disease – A Danish Nationwide Study of 1·3 Million Individuals. EClinicalMedicine. 2019;7:21–6. DOI: 10.1016/j.eclinm.2019.01.004

24. Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulmonary Medicine. 2012;12(1):48. DOI: 10.1186/1471-2466-12-48

25. van Gestel YRBM, Hoeks SE, Sin DD, Welten GMJM, Schouten O, Witteveen HJ et al. Impact of Cardioselective β-Blockers on Mortality in Patients with Chronic Obstructive Pulmonary Disease and Atherosclerosis. American Journal of Respiratory and Critical Care Medicine. 2008;178(7):695–700. DOI: 10.1164/rccm.200803-384OC

26. Hawkins NM, Petrie MC, MacDonald MR, Jhund PS, Fabbri LM, Wikstrand J et al. Heart Failure and Chronic Obstructive Pulmonary Disease. Journal of the American College of Cardiology. 2011;57(21):2127–38. DOI: 10.1016/j.jacc.2011.02.020

27. Su T-H, Chang S-H, Kuo C-F, Liu P-H, Chan Y-L. β-blockers after acute myocardial infarction in patients with chronic obstructive pulmonary disease: A nationwide population-based observational study. PLOS ONE. 2019;14(3):e0213187. DOI: 10.1371/journal.pone.0213187

28. Petta V, Perlikos F, Loukides S, Bakakos P, Chalkias A, Iacovidou N et al. Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease. Heart Failure Reviews. 2017;22(6):753–63. DOI: 10.1007/s10741-017-9646-z

29. Lin R, Peng H, Nguyen LP, Dudekula NB, Shardonofsky F, Knoll BJ et al. Changes in β2-adrenoceptor and other signaling proteins produced by chronic administration of ‘β-blockers’ in a murine asthma model. Pulmonary Pharmacology & Therapeutics. 2008;21(1):115–24. DOI: 10.1016/j.pupt.2007.06.003

30. Ekström MP, Hermansson AB, Ström KE. Effects of Cardiovascular Drugs on Mortality in Severe Chronic Obstructive Pulmonary Disease: A Time-Dependent Analysis. American Journal of Respiratory and Critical Care Medicine. 2013;187(7):715–20. DOI: 10.1164/rccm.201208-1565OC

31. Dorow P, Thalhofer S, Bethge H, Disselhoff G, Wagner G. Long-Term Treatment of Angina Pectoris with Bisoprolol or Atenolol in Patients with Chronic Obstructive Bronchitis: A Randomized, Double-Blind Crossover Study. Journal of Cardiovascular Pharmacology. 1990;16(Suppl 5):S36–44. DOI: 10.1097/00005344-199006165-00008

32. Bova A.A., Lapitskiy D.V. Modern approaches to the diagnosis and treatment of coronary heart disease in patients with chronic obstructive pulmonary disease. Medical news. 2007;9:7–14. https://www.mednovosti.by/journal.aspx?article=208

33. Dransfield MT, Voelker H, Bhatt SP, Brenner K, Casaburi R, Come CE et al. Metoprolol for the Prevention of Acute Exacerbations of COPD. New England Journal of Medicine. 2019;381(24):2304–14. DOI: 10.1056/NEJMoa1908142

34. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H et al. Expert consensus document on beta-adrenergic receptor blockers. Cardiovascular Therapy and Prevention. 2005;4(1):99–124.

35. Ni Y, Shi G, Wan H. Use of Cardioselective ß-Blockers in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized, Placebo-controlled, Blinded Trials. Journal of International Medical Research. 2012;40(6):2051–65. DOI: 10.1177/030006051204000602

36. Mentz RJ, Wojdyla D, Fiuzat M, Chiswell K, Fonarow GC, O’Connor CM. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). The American Journal of Cardiology. 2013;111(4):582–7. DOI: 10.1016/j.amjcard.2012.10.041

37. Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax. 2012;67(11):977–84. DOI: 10.1136/thoraxjnl-2012-201945

38. Huang YL, Lai C-C, Wang Y-H, Wang C-Y, Wang J-Y, Wang H-C et al. Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2017;12:2987–96. DOI: 10.2147/COPD.S145913

39. Dorow P, Bethge H, Tonnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. European Journal of Clinical Pharmacology. 1986;31(2):143–7. DOI: 10.1007/BF00606650

40. Hawkins NM, MacDonald MR, Petrie MC, Chalmers GW, Carter R, Dunn FG et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. European Journal of Heart Failure. 2009;11(7):684–90. DOI: 10.1093/eurjhf/hfp066

41. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax. 2008;63(4):301–5. DOI: 10.1136/thx.2007.081893

42. Lainscak M, Podbregar M, Kovacic D, Rozman J, von Haehling S. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respiratory Medicine. 2011;105(Suppl 1):S44–9. DOI: 10.1016/S0954-6111(11)70010-5

43. Kubota Y, Asai K, Furuse E, Nakamura S, Murai K, Tsukada YT et al. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease. 2015;10(1):515–23. DOI: 10.2147/COPD.S79942

44. Su VY-F, Chang Y-S, Hu Y-W, Hung M-H, Ou S-M, Lee F-Y et al. Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease. Medicine. 2016;95(5):e2427. DOI: 10.1097/MD.0000000000002427

45. Sirak TE, Jelic S, Le Jemtel TH. Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. Journal of the American College of Cardiology. 2004;44(3):497–502. DOI: 10.1016/j.jacc.2004.03.063

46. Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. The Journal of Heart and Lung Transplantation. 2002;21(12):1290–5. DOI: 10.1016/S1053-2498(02)00459-X

47. Sessa M, Mascolo A, Scavone C, Perone I, Di Giorgio A, Tari M et al. Comparison of Long-Term Clinical Implications of Beta-Blockade in Patients With Obstructive Airway Diseases Exposed to Beta-Blockers With Different β1-Adrenoreceptor Selectivity: An Italian Population-Based Cohort Study. Frontiers in Pharmacology. 2018;9:1212. DOI: 10.3389/fphar.2018.01212

48. Baker JG. The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3-adrenoceptors: β-Blockers and β-adrenoceptor selectivity. British Journal of Pharmacology. 2005;144(3):317–22. DOI: 10.1038/sj.bjp.0706048

49. Çamsarı A, Arıkan S, Avan C, Kaya D, Pekdemir H, ÇiÇek D et al. Metoprolol, a Β-1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. Heart and Vessels. 2003;18(4):188–92. DOI: 10.1007/s00380-003-0706-z

50. Maffei A, Lembo G. Nitric oxide mechanisms of nebivolol. Therapeutic Advances in Cardiovascular Disease. 2009;3(4):317–27. DOI: 10.1177/1753944709104496

51. van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest. 2005;127(3):818–24. DOI: 10.1378/chest.127.3.818

52. Dransfield MT, McAllister DA, Anderson JA, Brook RD, Calverley PMA, Celli BR et al. β-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT. Annals of the American Thoracic Society. 2018;15(5):608–14. DOI: 10.1513/AnnalsATS.201708-626OC

53. Jabbal S, Anderson W, Short P, Morrison A, Manoharan A, Lipworth BJ. Cardiopulmonary interactions with beta-blockers and inhaled therapy in COPD. QJM: An International Journal of Medicine. 2017;110(12):785–92. DOI: 10.1093/qjmed/hcx155

54. Narayanan K, Reinier K, Uy-Evanado A, Teodorescu C, Zhang L, Chugh H et al. Chronic Obstructive Pulmonary Disease and Risk of Sudden Cardiac Death. JACC: Clinical Electrophysiology. 2015;1(5):381–7. DOI: 10.1016/j.jacep.2015.06z